This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Nappi A, Gallicchio R, Simeon V, Nardelli A, Pelagalli A, Zupa A, et al. [F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients. Radiol Oncol 2015; 49: 320-6. doi: 10.1515/raon-2015-0043NappiAGallicchioRSimeonVNardelliAPelagalliAZupaAet al[F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patientsRadiol Oncol201549320610.1515/raon-2015-0043Open DOISearch in Google Scholar
Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, et al. Panel members. 2nd ESMO consensus conference in lung cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol 2015; 26: 1573-88. doi: 10.1093/annonc/mdv187EberhardtWEDe RuysscherDWederWLe PéchouxCDe LeynPHoffmannHet alPanel members2nd ESMO consensus conference in lung cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol20152615738810.1093/annonc/mdv187Open DOISearch in Google Scholar
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 706-14. doi: 10.1097/JTO.0b013e31812f3c1aGoldstrawPCrowleyJChanskyKGirouxDJGroomePARami-PortaRet alThe IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumoursJ Thorac Oncol200727061410.1097/JTO.0b013e31812f3c1aOpen DOISearch in Google Scholar
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 39-51. doi: 10.1016/j.jtho.2015.09.009.GoldstrawPChanskyKCrowleyJRami-PortaRAsamuraHEberhardtWEet alInternational Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating InstitutionsThe IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol201611395110.1016/j.jtho.2015.09.009Open DOISearch in Google Scholar
Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol 2008; 26: 3552-9. doi: 10.1200/ JCO.2007.13.9030PignonJPTribodetHScagliottiGVDouillardJYShepherdFAStephensRJet alLung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative groupJ Clin Oncol2008263552910.1200/JCO.2007.13.9030Open DOISearch in Google Scholar
NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 2014; 383: 1561-71. doi: 10.1016/S0140-6736(13)62159-5NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant dataLancet201438315617110.1016/S0140-6736(13)62159-5Open DOISearch in Google Scholar
Betticher DC, Hsu Schmitz SF, Totsch M, Hansen E, Joss C, von Briel C, et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006; 94: 1099-106.BetticherDCHsuSchmitz SFTotschMHansenEJossCvon BrielCet alPrognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II studyBr J Cancer200694109910610.1038/sj.bjc.6603075Search in Google Scholar
Sher DJ, Fidler MJ, Liptay MJ, Koshy M. Comparative effectiveness of neo-adjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. Lung Cancer 2015; 88: 267-74. doi: 10.1016/j.lungcan.2015.03.015SherDJFidlerMJLiptayMJKoshyMComparative effectiveness of neo-adjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancerLung Cancer2015882677410.1016/j.lungcan.2015.03.015Open DOISearch in Google Scholar
Thomas M, Rube C, Hoffknecht P, Macha HN, Freitag L, Linder A, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 2008; 9: 636-48. doi: 10.1016/S1470-2045(08)70156-6ThomasMRubeCHoffknechtPMachaHNFreitagLLinderAet alEffect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancerLancet Oncol200896364810.1016/S1470-2045(08)70156-6Open DOISearch in Google Scholar
Garrido P, Gonzalez-Larriba JL, Insa A, Provencio M, Torres A, Isla D, et al. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non-small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol 2007; 25: 4736-42.GarridoPGonzalez-LarribaJLInsaAProvencioMTorresAIslaDet alLong-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non-small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901J Clin Oncol20072547364210.1200/JCO.2007.12.0014Search in Google Scholar
Barlési F, Doddoli C, Torre JP, Giudicelli R, Fuentes P, Thomas P, et al. Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy. Eur J Cardiothorac Surg 2005; 28: 629-34. doi: 10.1016/j.ejcts.2005.06.018BarlésiFDoddoliCTorreJPGiudicelliRFuentesPThomasPet alComparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapyEur J Cardiothorac Surg2005286293410.1016/j.ejcts.2005.06.018Open DOISearch in Google Scholar
Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010 28: 2181-90. doi: 10.1200/JCO.2009.26.2543AuperinALe PechouxCRollandECurranWJFuruseKFournelPet alMeta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancerJ Clin Oncol20102821819010.1200/JCO.2009.26.2543Open DOISearch in Google Scholar
Ma L, Men Y, Feng L, Kang J, Sun X, Yuan M, et al. A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer. Radiol Oncol 2019; 53: 6-14. doi: 10.2478/raon-2019-0006MaLMenYFengLKangJSunXYuanMet alA current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancerRadiol Oncol20195361410.2478/raon-2019-0006Open DOISearch in Google Scholar
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377: 1919-29. doi: 10.1056/ NEJMoa1709937AntoniaSJVillegasADanielDVicenteDMurakamiSHuiRet alPACIFIC InvestigatorsDurvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med201737719192910.1056/NEJMoa1709937Open DOISearch in Google Scholar
Zhang Z, Sun J. Interval censoring. Stat Methods Med Res 2010; 19: 53-70. doi: 10.1177/0962280209105023ZhangZSunJInterval censoringStat Methods Med Res201019537010.1177/0962280209105023Open DOISearch in Google Scholar
Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, et al. PROCLAIM: Randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2016; 34: 953-62. doi: 10.1200/JCO.2015.64.8824SenanSBradeAWangLHVansteenkisteJDakhilSBiesmaBet alPROCLAIM: Randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancerJ Clin Oncol2016349536210.1200/JCO.2015.64.8824Open DOISearch in Google Scholar
Ramlau R, Cufer T, Berzinec P, Dziadziuszko R, Olszewski W, Popper H, et al. INSIGHT study team. Epidermal growth factor receptor mutation-positive non-small-cell lung cancer in the real-world setting in Central Europe: The INSIGHT Study. 10: 1370-4. J Thorac Oncol 2015; 10: 1370-4. doi: 10.1097/ JTO.0000000000000621RamlauRCuferTBerzinecPDziadziuszkoROlszewskiWPopperHet alINSIGHT study teamEpidermal growth factor receptor mutation-positive non-small-cell lung cancer in the real-world setting in Central Europe: The INSIGHT Study. 10 1370(4) J Thorac Oncol2015101370410.1097/JTO.0000000000000621Open DOISearch in Google Scholar
Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, et al. Biomarkers France contributors. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016; 387: 1415-26. doi: 10.1016/S0140-6736(16)00004-0BarlesiFMazieresJMerlioJPDebieuvreDMosserJLenaHet alBiomarkers France contributorsRoutine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet201638714152610.1016/S0140-6736(16)00004-0Open DOISearch in Google Scholar
Hofman P. ALK in Non-Small Cell Lung Cancer (NSCLC): pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practice. Cancers 2017; 9: pii: E107. doi: 10.3390/cancers9080107HofmanPALK in Non-Small Cell Lung Cancer (NSCLC): pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practiceCancers20179pii: E10710.3390/cancers9080107Open DOISearch in Google Scholar
Ryan KJ, Skinner KE, Fernandes AW, Punekar RS, Pavilack M, Walker MS, et al. Real-world outcomes in patients with unresected stage III non-small cell lung cancer. Med Oncol 2019; 36: 24. doi: 10.1007/s12032-019-1249-1RyanKJSkinnerKEFernandesAWPunekarRSPavilackMWalkerMSet alReal-world outcomes in patients with unresected stage III non-small cell lung cancerMed Oncol2019362410.1007/s12032-019-1249-1Open DOISearch in Google Scholar
Ryan KJ, Skinner KE, Fernandes AW, Punekar RS, Pavilack M, Walker MS, et al. Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer. Future Oncol 2019; 15: 2943-53. doi: 10.2217/ fon-2018-0939RyanKJSkinnerKEFernandesAWPunekarRSPavilackMWalkerMSet alReal-world treatment patterns among patients with unresected stage III non-small-cell lung cancerFuture Oncol20191529435310.2217/fon-2018-0939Open DOISearch in Google Scholar
Moore S, Leung B, Wu J, Ho C. Real-world treatment of stage III NSCLC: the role of trimodality treatment in the era of immunotherapy. J Thorac Oncol 2019; 14: 1430-9. doi: 10.1016/j.jtho.2019.04.005MooreSLeungBWuJHoCReal-world treatment of stage III NSCLC: the role of trimodality treatment in the era of immunotherapyJ Thorac Oncol2019141430910.1016/j.jtho.2019.04.005Open DOISearch in Google Scholar
Fernandes AT, Mitra N, Xanthopoulos E, Evans T, Stevenson J, Langer C, et al. The impact of extent and location of mediastinal lymph node involvement on survival in stage III non-small cell lung cancer patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2012; 83: 340-7. doi: 10.1016/j.ijrobp.2011.05.070FernandesATMitraNXanthopoulosEEvansTStevensonJLangerCet alThe impact of extent and location of mediastinal lymph node involvement on survival in stage III non-small cell lung cancer patients treated with definitive radiotherapyInt J Radiat Oncol Biol Phys201283340710.1016/j.ijrobp.2011.05.070Open DOISearch in Google Scholar
Van der Meer FS, Schramel FM, Van Vulpen M, El Sharouni SY. Feasibility of concomitant chemoradiotherapy in daily practice for patients with NSCLC stage III. Anticancer Res 2016; 36: 4673-6. doi: 10.21873/anticanres.11019Vander Meer FSSchramelFMVanVulpen MElSharouni SYFeasibility of concomitant chemoradiotherapy in daily practice for patients with NSCLC stage IIIAnticancer Res2016364673610.21873/anticanres.11019Open DOISearch in Google Scholar
Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374: 379-86. doi: 10.1016/S0140-6736(09)60737-6AlbainKSSwannRSRuschVWTurrisiAT3rdShepherdFASmithCet alRadiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trialLancet20093743798610.1016/S0140-6736(09)60737-6Open DOISearch in Google Scholar
